Ischemix, Inc.
Clinical-stage pharmaceutical company with portfolio of therapeutics for prevention and treatment of serious cardiac and renal conditions.
- Stage Product In Development
- Industry Biotechnology
- Location Maynard, MA, USA
- Currency USD
- Founded June 1999
- Employees 7
- Website ischemix.com
Company Summary
Ischemix is a privately-held, clinical-phase pharmaceutical company developing a portfolio of therapeutic compounds for the prevention and treatment of serious cardio-renal conditions. There are no currently available therapies for the conditions the Company seeks to treat. Ischemix expects to initially market its lead compound to the critical care area of the hospital.
Team
-
David DeWahlPresident and Chief Executive Officer
Mr. DeWahl joined Ischemix in January 2013 as President and Chief Executive Officer. He was previously Vice President of Corporate Development for Helix Therapeutics, Inc. Mr. DeWahl is also a co-founder of Life Science Pharmaceuticals, Inc., which is developing novel therapeutics to treat cancer, diabetes and other serious illnesses. Mr. DeWahl was previously an investment banker focused on the health care and life sciences industry
Advisors
-
Cooley LLPLawyerUnconfirmed
Previous Investors
-
Reinier Beeuwkes PhDUnconfirmedGeoffrey Clark MDUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.